Paper Details

  1. Home
  2. Paper Details

In Vitro Comparison of the Effects of Imatinib and Ponatinib on Chronic Myeloid Leukemia Progenitor/Stem Cell Features.

Author: CaporaleRoberto, CheloniGiulia, Dello SbarbaPersio, GozziniAntonella, LombardiZoe, PotetiMartina, RovidaElisabetta, ScappiniBarbara, SilvanoAngela, TubitaAlessandro, TusaIgnazia

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Tyrosine kinase inhibitors (TKIs) have revolutionized the treatment of chronic myeloid leukemia (CML), a type of blood cancer. However, patients can develop resistance to TKIs, and the disease can return after treatment is stopped. Although TKIs are still the only current treatment option for CML, more research is needed to develop new treatments that can overcome resistance and prevent disease relapse.
Paper Details　
Original Abstract of the Article :
The development of molecularly tailored therapeutic agents such as the BCR/ABL-active tyrosine kinase inhibitors (TKi) resulted in an excellent treatment option for chronic myeloid leukemia (CML) patients. However, following TKi discontinuation, disease relapses in 40-60% of patients, an occurrence ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7568716/

データ提供：米国国立医学図書館（NLM）

Chronic Myeloid Leukemia: A Quest for Lasting Solutions

Chronic Myeloid Leukemia (CML) research is an ongoing journey, much like a camel traversing a vast desert, seeking oases of knowledge. This research delves into the realm of targeted therapies for CML, focusing on the effectiveness of tyrosine kinase inhibitors (TKIs) like imatinib and ponatinib against leukemia progenitor/stem cells. These TKIs have emerged as powerful weapons against CML, but their limitations are like mirages in the desert – enticing but elusive.

The Resilience of Leukemia Stem Cells: A Challenging Landscape

The study reveals that even with TKIs, disease relapses are common, suggesting the persistence of leukemia stem cells that are less susceptible to these therapies. These resilient cells are like hardy desert plants that thrive in harsh conditions, making CML treatment a constant battle.

TKIs: A Beacon of Hope in a Challenging Terrain

Despite the challenges, TKIs remain the current therapeutic mainstay for CML patients, offering a ray of hope in the midst of this challenging disease. The research underscores the need for further exploration into overcoming the limitations of these therapies and developing strategies to target those elusive leukemia stem cells.

Dr.Camel's Conclusion

This research sheds light on the enduring challenge of CML treatment, highlighting the resilience of leukemia stem cells. It emphasizes the ongoing search for innovative therapies that can effectively target these cells and achieve lasting remission. As researchers continue their exploration, we may one day discover a cure for CML, just as explorers discovered new oases in the desert.
Date :
  1. Date Completed 2021-11-01
  2. Date Revised 2021-11-01
Further Info :

Pubmed ID

32780298

DOI: Digital Object Identifier

PMC7568716

Related Literature

Article Analysis
・Effects of imatinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.